8-K current report · filed Oct 15, 2026

AbbVie Inc (ABBV) 8-K Current Report: October 15, 2026

Item 5.02ABBV overview

Short answer

AbbVie Inc (ABBV) filed an 8-K current report with the SEC on October 15, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Board expanded from 12 to 13 directors through appointment of Dr. John M. Carethers.

AbbVie Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Board expanded from 12 to 13 directors through appointment of Dr. John M. Carethers
  • Carethers classified independent under NYSE and AbbVie governance standards, supporting board oversight credibility
  • Appointment to Public Policy and Sustainability Committee adds healthcare and policy expertise
  • Independent-director compensation governed by terms disclosed in AbbVie’s March 31, 2025 Form 10-Q exhibit

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other AbbVie Inc 8-K filings

Get the next ABBV 8-K as it lands

Follow ABBV for push alerts, or ask the research agent what this filing means.